Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Who owns healthcare Now?

Invest in the platforms, that’s where healthcare value lives now...

Ethtry Plc sets out refreshed operating strategy

Ethtry PLC has adopted a refreshed operating strategy, confirming its strategic focus on breakthrough technologies including quantum technologies, artificial intelligence, data centres, energy transition and Web3, alongside its ongoing Ethereum Treasury Policy...

Brava Health partners with AMV to add movement intelligence to Health OS

Brava Health announced a strategic partnership with Academy Medtech Ventures to embed AI-powered movement intelligence into Brava Health OS...

Ethtry Plc purchases 500 Ethereum as part of treasury strategy

Ethtry has acquired 500 Ethereum at an average price of £2,412 per ETH, investing £1.205 million as part of the ongoing implementation of its Ethereum Treasury Policy...

AstraZeneca to move Nasdaq listing to NYSE

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq Stock Market LLC...

Medical office real estate holds firm amid broader market shifts

Medical office properties continue to attract investors as stable demand and long leases offer rare consistency in a shifting real estate market...

Oxford Nanopore Technologies to participate in January investor conferences

Oxford Nanopore Technologies will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London during January...

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine...

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements...

GSK Plc receives China approval for Nucala in COPD treatment

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils...

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD...

EDX Medical reports interim progress with revenue growth expected from diagnostics pipeline

EDX Medical Group has released its interim results for the six months to 20 September 2025, reporting continued progress across its diagnostics portfolio...

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has announced the UK launch of its BC95 bowel cancer testing service, designed to improve early detection and assess hereditary risk...

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over...

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...

Hikma Pharmaceuticals CEO Riad Mishlawi steps down, Executive Chairman assumes role

Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by mutual agreement...

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026...

Ethtry adds two new Advisory Board members

Ethtry has added Mike Foy and Marc Degen to its new Advisory Board, bringing experience across digital assets, fintech and Web3 ventures...
Search

Funds

November 24, 2025

Who owns healthcare Now?

Invest in the platforms, that’s where healthcare value lives now...

Ethtry Plc sets out refreshed operating strategy

Ethtry PLC has adopted a refreshed operating strategy, confirming its strategic focus on breakthrough technologies including quantum technologies, artificial intelligence, data centres, energy transition and Web3, alongside its ongoing Ethereum Treasury Policy...

Brava Health partners with AMV to add movement intelligence to Health OS

Brava Health announced a strategic partnership with Academy Medtech Ventures to embed AI-powered movement intelligence into Brava Health OS...

Ethtry Plc purchases 500 Ethereum as part of treasury strategy

Ethtry has acquired 500 Ethereum at an average price of £2,412 per ETH, investing £1.205 million as part of the ongoing implementation of its Ethereum Treasury Policy...

AstraZeneca to move Nasdaq listing to NYSE

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq Stock Market LLC...

Medical office real estate holds firm amid broader market shifts

Medical office properties continue to attract investors as stable demand and long leases offer rare consistency in a shifting real estate market...

Oxford Nanopore Technologies to participate in January investor conferences

Oxford Nanopore Technologies will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London during January...

GSK’s Shingrix Prefilled Syringe Approved in Europe

GSK has received European Commission approval for a prefilled syringe presentation of its Shingrix shingles vaccine...

Aptamer reports 27% revenue growth and signs multiple licensing deals in H1 FY26

Aptamer Group reported unaudited revenue of £0.83 million for the six months to 31 December 2025, a 27% increase year on year, supported by strong fee-for-service demand and the signing of multiple licensing agreements...

GSK Plc receives China approval for Nucala in COPD treatment

GSK plc has announced that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD characterised by raised blood eosinophils...

GSK Plc reaches US agreement to reduce prescription medicine costs

GSK has entered into an agreement with the US Administration to lower the cost of prescription medicines for American patients, including treatments across its respiratory portfolio for asthma and COPD...

EDX Medical reports interim progress with revenue growth expected from diagnostics pipeline

EDX Medical Group has released its interim results for the six months to 20 September 2025, reporting continued progress across its diagnostics portfolio...

EDX Medical launches BC95 bowel cancer testing service in the UK

EDX Medical Group has announced the UK launch of its BC95 bowel cancer testing service, designed to improve early detection and assess hereditary risk...

GSK secures FDA approval for Exdensur in severe eosinophilic asthma

GSK plc has received US FDA approval for Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and over...

Aptamer Group signs first licensing deal with Twist Bioscience

Aptamer Group has entered into its first licensing agreement with Twist Bioscience, granting a non-exclusive licence for the use of an Optimer® binder in hot-start PCR and next-generation sequencing products...

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer...

GSK Plc secures UK approval for Exdensur in asthma and nasal polyps

GSK has announced that Exdensur (depemokimab) has received marketing authorisation from the UK MHRA for use in certain asthma and chronic rhinosinusitis with nasal polyps patients...

Hikma Pharmaceuticals CEO Riad Mishlawi steps down, Executive Chairman assumes role

Hikma Pharmaceuticals has announced that Riad Mishlawi has stepped down as Chief Executive Officer and as a board member by mutual agreement...

GSK RSV vaccine recommended for wider adult use, CHMP backs expansion

GSK has announced that the EMA’s CHMP has recommended broadening the indication of its adjuvanted RSV vaccine to adults aged 18 and over, with a final decision expected in February 2026...

Ethtry adds two new Advisory Board members

Ethtry has added Mike Foy and Marc Degen to its new Advisory Board, bringing experience across digital assets, fintech and Web3 ventures...
Search

Funds

Health

FTSE 100

Funds